NEWNEURAL GETS SBIR GRANT FOR NN-818 STEM CELL TREATMENT.

 
FREE EXCERPT

NewNeural LLC, Lisle, Ill., a biotechnology company developing products to help the brain replace cells damaged or destroyed by disease or injury, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging at the National Institutes of Health. The grant provides additional resources for NewNeural to develop its small molecule, NN-818(TM). This compound has been shown, in aged animals, to significantly increase neural stem cells, thought to be an important part of the brain's internal healing mechanism. SBIR Grants are non-dilutive sources of funds that are awarded on a merit basis after peer review.

"This SBIR grant is important because it allows us to accelerate and broaden our work toward developing treatments for conditions that are desperately seeking solutions," said Robert Gonzalez, president & CEO of NewNeural. "This grant and the previously...

To continue reading

FREE SIGN UP